Sam Possemiers

Company: MRM Health

Job title: Chief Executive Officer

Seminars:

Clinical Updates from Phase 2a Studies with Optimised Consortia Therapeutic MH002 in Ulcerative Colitis & Pouchitis 8:30 am

MH002, a 6-strain consortia therapeutic designed, optimised and manufactured through MRM Health’s CORAL® technology, is the most advanced live biotherapeutic in clinical development for Ulcerative Colitis and Pouchitis Having completed full analysis, sharing additional insights of MH002’s activity Sharing microbiome and engraftment data, for the mechanism of action of MH002Read more

day: Conference Day One